VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering
Summary
Up to $1.9 million up front with up to an additional $2.7 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrantsHENDERSON, Nev., December 6, 2024/PRNewswire/VolitionRx Limited (NYSE AMERICAN: VNRX) (Volition or the Company), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of (i) 445,648 shares of its common stock to certain directors and executive officers of the Company (the Insiders) at an offering price of $0.5722 per share, and (ii) 2,857,389 shares of its common stock, together with common stock purchase warrants, composed of Form A warrants to purchase up to 2,857,389 shares of common stock and Form B warrants to purchase up to 1,428,693 shares of common stock (collectively, the Warrants), to other investors at a combined offering price of $0.5722 per share and accompanying warrants. Volition expects to use the net proceeds of the offering for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes.The securities described above are being offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also improve their quality of life.Volitions research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in Nevada, London and Singapore.Statements in this press release may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of management and include statements regarding the expected use of net proceeds from the offering, the exercise of the Warrants prior to their expiration, the satisfaction of customary closing conditions related to the offering and sale of securities, and Volitions ability to complete the offering. Forward-looking statements are subject to risks and uncertainties that may cause Volitions actual activities or results to differ materially from those indicated or implied by any forward-looking statement, including, without limitation, due to risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the offering, and risks disclosed in the documents Volition files from time to time with the SEC, including Volitions Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.